Every successful person always has a trigger. Most times the height a man attends is proportionate to how big the trigger is. Siegall father die of cancer, can there be a bigger trigger than to see someone you love die of a particular ailment. Most people will give whatever it takes to obliterate that wicked disease from existence as punishment for the havoc it did on their love ones. Siegall disclosed this fact about his biological father in an interview, and that in my own opinion is the bedrock of his outstanding success in his chosen profession. I am of the opinion he chose to pursue the branch of medicine that addresses cancer to pay the disease in its own coin, and from every indication this noble fellow has accomplished that and still keeps dealing devastating blows on cancer. I guess he will not stop the onslaught until the name cancer is wiped out of our dictionaries. For those who do not know the extent this fellow has gone in helping patients of cancer, lets take a stroll, and I will let you into some few of the numerous outstanding feats of the great personality because space is not our friend in this write-up.
Clay B. Siegall set the ball rolling with adequate preparation for the task ahead. He headed for the University of Maryland where he earned his B.S. in Zoology before moving to George Washington University for a Ph.D. in Genetics. He spent quality time working with the Bristol-Myers Squibb Pharmaceutical Research Institute between 1991 and 1997. Before joining Bristol-Myers, he was with the National Cancer Institute and the National Institutes of Health from as far back as 1988.
Obviously, his most glorious time started in 1998 when he co-founded Seattle Genetics and became the company’s President, Chief Executive Officer and Board’s Chairman. He has been occupying these positions to this very day with amazing successes as proves of his outstanding leadership pedigree. Under his watch, the company secured the FDA approval of its first antibody-drug conjugate (ADC) product by the name ADCETRIS® (brentuximab vedotin). The drug is now in use in more than 65 countries for the treatment of cancer.
Here is a man with 15 patents to his name, several international awards, over 70 publications on issues pertaining to cancer and with a large heart for people suffering from cancer. Clay B. Siegall has done much to clear the way for the eventual defeat of the monster called cancer.